Minerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016
(Thomson Reuters ONE) -
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
(NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the
development of innovative therapies to treat central nervous system (CNS)
disorders, today announced that it will present at the Jefferies 2016 Healthcare
Conference on June 8, 2016 at 11:00 a.m. Eastern Time.
The Company will present further data from the Phase IIb trial with MIN-101 in
schizophrenia and the Phase IIa trial with MIN-117 in major depressive disorder
(MDD). Top line results from these studies were announced on May 26, 2016.
Additional information from recent MIN-202 studies carried out in insomnia and
MDD will also be presented. Top line results from both of these studies were
announced earlier this year. MIN-202 is under joint development with Janssen
Pharmaceutica NV.
The presentation will be web cast and accessible through the investor relations
section of the Company's web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva's proprietary compounds include: MIN-101, which has
successfully completed Phase IIb development for schizophrenia; MIN-202 (JNJ-
42847922), which has successfully completed Phase IIa and Phase Ib clinical
trials in insomnia and MDD, respectively; MIN-117, which has successfully
completed Phase IIa development for MDD; and MIN-301, in pre-clinical
development for Parkinson's disease. Minerva's common stock is listed on the
NASDAQ Global Market under the symbol "NERV." For more information, please
visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via GlobeNewswire
[HUG#2016955]
Datum: 01.06.2016 - 14:30 Uhr
Sprache: Deutsch
News-ID 475026
Anzahl Zeichen: 2648
contact information:
Town:
Waltham
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 258 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Minerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Minerva Neurosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
